Persistent URL of this record https://hdl.handle.net/1887/3714019
Documents
-
- Download
- ciad141
- Publisher's Version
-
open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Clinical impact of polymerase chain reaction-based Aspergillus and azole resistance detection in invasive aspergillosis: a prospective multicenter study
Background
Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy.
Methods
In a prospective study, we evaluated the clinical value of the AsperGenius polymerase chain reaction (PCR) assay in hematology patients from 12 centers. This PCR assay detects the most frequent cyp51A mutations in A. fumigatus conferring azole resistance. Patients were included when a computed tomography scan showed a pulmonary infiltrate and bronchoalveolar fluid (BALf) sampling was performed. The primary end point was antifungal treatment failure in patients with azole-resistant IA.
Results
Of 323 patients enrolled, complete mycological and radiological information was available for 276 (94%), and probable IA was diagnosed in 99/276 (36%). Sufficient BALf for PCR testing...
Show moreBackground
Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy.
Methods
In a prospective study, we evaluated the clinical value of the AsperGenius polymerase chain reaction (PCR) assay in hematology patients from 12 centers. This PCR assay detects the most frequent cyp51A mutations in A. fumigatus conferring azole resistance. Patients were included when a computed tomography scan showed a pulmonary infiltrate and bronchoalveolar fluid (BALf) sampling was performed. The primary end point was antifungal treatment failure in patients with azole-resistant IA.
Results
Of 323 patients enrolled, complete mycological and radiological information was available for 276 (94%), and probable IA was diagnosed in 99/276 (36%). Sufficient BALf for PCR testing was available for 293/323 (91%). Aspergillus DNA was detected in 116/293 (40%) and A. fumigatus DNA in 89/293 (30%). The resistance PCR was conclusive in 58/89 (65%) and resistance detected in 8/58 (14%). Two had a mixed azole-susceptible/azole-resistant infection. In the 6 remaining patients, treatment failure was observed in 1. Galactomannan positivity was associated with mortality (P = .004) while an isolated positive Aspergillus PCR was not (P = .83).
Conclusions
Real-time PCR-based resistance testing may help to limit the clinical impact of triazole resistance. In contrast, the clinical impact of an isolated positive Aspergillus PCR on BALf seems limited. The interpretation of the EORTC/MSGERC PCR criterion for BALf may need further specification (eg, minimum cycle threshold value and/or PCR positive on >1 BALf sample).
Show less- All authors
- Huygens, S.; Dunbar, A.; Buil, J.B.; Klaassen, C.H.W.; Verweij, P.E.; Dijk, K. van; Jonge, N. de; Janssen, J.J.W.M.; Velden, W.J.F.M. van der; Biemond, B.J.; Bart, A.; Bruns, A.H.W.; Haas, P.J.A.; Demandt, A.M.P.; Oudhuis, G.; Borne, P. von dem; Beek, M.T. van der; Klein, S.K.; Godschalk, P.; Span, L.F.R.; Postma, D.F.; Kampinga, G.A.; Maertens, J.; Lagrou, K.; Mercier, T.; Moors, I.; Boelens, J.; Selleslag, D.; Reynders, M.; Zandijk, W.; Doorduijn, J.K.; Cornelissen, J.J.; Schauwvlieghe, A.F.A.D.; Rijnders, B.J.A.
- Date
- 2023-03-11
- Journal
- Clinical Infectious Diseases
- Volume
- 77
- Issue
- 1
- Pages
- 38 - 45